SCHEMBL25552011

SCHEMBL25552011

COC(=O)c1ncc(C)c(-c2ccccc2F)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MBNL1 Q9NR56 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HTR5A P47898 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ CTSA P10619 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TACR3 P29371 1/20 0.38
▸ CCKAR P32238 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ HPGD P15428 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ADORA2A P29274 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036976 1.00 MBNL1 (0.43) MBNL1ALDH1A1HTR5AJAK2JAK3
SCHEMBL30036962 0.90 CTSA (0.39) ALDH1A1JAK2NPC1RAB9ACTSA
SCHEMBL25551949 0.90 CTSA (0.39) ALDH1A1JAK2NPC1RAB9ACTSA
SCHEMBL25552003 0.85 MBNL1 (0.47) MBNL1HTR5ANPC1RAB9ADHODH
SCHEMBL30037130 0.85 MBNL1 (0.47) MBNL1HTR5ANPC1RAB9ADHODH
SCHEMBL25559613 0.84 DHODH (0.43) ALDH1A1DHODHCTSAADORA2AADORA2B
SCHEMBL30036500 0.83 HTR5A (0.48) MBNL1ALDH1A1HTR5AJAK2JAK3
SCHEMBL25552013 0.82 CYP4F2 (0.43) ALDH1A1JAK2JAK3NPC1RAB9A
SCHEMBL24572726 0.80 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL30037120 0.79 CTSA (0.44) CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 — — US disclosed
CN-115515940-A Inhibitors of receptor interacting protein kinase I for the treatment of disease 德州大学系统董事会 2022-12-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 MBNL1 1407/4885ALDH1A1 4554/4885HTR5A 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback